Cognetivity Neurosciences Ltd. (CSE: CGN) (FWB:1UB) announced that it has received two key patent application approvals from the European and United States Patent Offices.

Both patents have been granted against Cognetivity’s proprietary Integrated Cognitive Assessment, an artificial-intelligence system to assess mental health disorders in humans. The system’s initial focus is on early diagnosis of dementia, in particular Alzheimer’s Disease, by detection of the early stages of loss of cognitive performance associated with the disease.

Securing patent approvals in two of the largest future markets for Cognetivity’s technology   supports the Company’s documented growth strategy and paves the way for the company to selectively develop its market opportunities while it drives towards full commercialization over the coming months.

Cognetivity’s CEO and Director, Dr. Sina Habibi said: “Securing patents in key markets for our technology is a major company milestone and something we’ve worked very hard to achieve. This protection of our unique and innovative technology puts us in a strong position as we move through the final stages of the regulatory process, finalize our clinical product and launch a commercial product within these territories.”

About Cognetivity Neurosciences Ltd.

Cognetivity is a technology company developing a cognitive testing platform, the Integrated Cognitive Assessment (ICA) for use in medical and commercial environments. Cognetivity’s ICA uses Artificial Intelligence and machine learning techniques to help detect the earliest signs of impairment by testing the performance of large areas of the brain, potentially allowing early diagnosis of dementia. Cognetivity aims to develop the ICA through planned clinical studies to the market in North America and Europe.